Favourable prognostic factors in therapy related acute myeloid leukaemia

Srpski Arhiv za Celokupno Lekarstvo

Volumn 139, Issue 5-6, 2011, Pages 347-352

  Antonijević, Nebojša ^a,b   Suvajdžić, Nada ^a,b   Terzić, Tatjana ^b   Jakovljević, Branko ^b   Janković, Gradimir ^a,b   Elezović, Ivo ^a   Milošević, Rajko ^a   Čolović, Milica ^a,b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Cytology; Myelodysplasia; Survival; Therapy related acute myeloid leukaemia

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CHROMOSOME ANALYSIS; FEMALE; GENETICS; GRANULOCYTE; HUMAN; KARYOTYPING; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RADIOTHERAPY; SECOND CANCER; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; CYTOGENETIC ANALYSIS; FEMALE; GRANULOCYTES; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RADIOTHERAPY; SURVIVAL RATE;

EID: 80053056249     PISSN: 03708179     EISSN: None     Source Type: Journal    
DOI: 10.2298/SARH1106347A     Document Type: Article

References (33)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. Therapy-related myeloid neoplasms. In: Swerdlow, Campo, E, Harris, NL, et al. WHO Classification of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008. p.127-9.
2. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukaemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007; 92:1389-98.
3. Ono M, Watanabe T, Shimizu C, Hiramoto N, Goto Y, Yonemori K, et al. Therapy-related acute promyelocytic leukaemia caused by hormonal therapy and radiation in a patient with recurrent breast cancer. Jpn J Clin Oncol. 2008; 38(8):567-70.
4. Larson RA. Etiology and management of therapy-related myeloid leukaemia. Hematology Am Soc Hematol Educ Program. 2007:453-9.
5. Suresh V, Attili S, Dadhich HK, Sundereshan TS, Bapsy PP, Sahoo TP, et al. Therapy related acute promyelocytic leukaemia. Indian J Med Paediatr Oncol. 2006; 27(1):32-4.
6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndrome. Br J Haematol. 1982; 51:89-99.
7. Berg S, Poplack DG. Clinical manifestation of acute lymphocytic leukaemia in children. In: Hoffman R, et al, editors. Hematology, Basic Principles and Practice. New York: Churchill Linivngstone; 1995. p.1067-74.
8. Beveridge D, Urtasun A. Therapy-related acute leukaemia and myelotic syndrome. Ann Intern Med. 2003; 20:257-68.
9. Brito-Babapulle F, Catovsky D, Galton DAG, Boiron D. Acute nonlymphocytic leukaemia following FAM combination adjuvant chemotherapy for gastric and lung adenocarcinoma. Br J Haematol. 1987; 66:445-50.
10. Deiss A. Therapy related MDS and acute leukaemia. In: Lee RG, Bithell TC, Foerster J, Athens JW, Lukens WB, editors. Wintrobe's Clinical Hematology. 9th ed. Philadelphia: Lea Febiger; 1993. p.1955-8.
11. Estienne MH, Fenaux P, Preudhomme C, Lai JL, Zandecki M, Lepelley P, et al. Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia - a report on 132 patients. Clin Lab Haemat. 1990; 12:57-65.
12. Haase D, Binder C, Bunger J, Fonatsch C, Streubel C, Schnittger S, et al. Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk Res. 2002; 26:249-54.
13. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organisation classification of hematological malignancies report of the Clinical Advisory Committee Meeting. Airlie House. Virginia, November 1997. Mod Pathol. 2000; 13:193-207.
14. Heim S, Mittelman F. An International System for Human Cytogenetic Nomenclature. In: Mitelman F, editor. Basel, Switzerland: S. Karger AG Publishers; 1995. p.27-84. www.srp-arh.rs.
15. Iurlo A, Mecucci C, Van Orshoven A, Michaux JL, Boogaerts M, Noens L, et al. Cytogenetic and clinical investigation in 76 cases with therapy-related leukaemia and myelodysplastic syndrome. Cancer Genet Cytogenet. 1989; 43:227-41.
16. Kantarjian HM, Keating JM. Therapy related leukaemia and myelodysplastic syndrome. Semin Oncol. 1987; 14:435-43.
17. Levine GE, Blomfield DC. Secondary myelodysplastic syndromes and leukaemias. Clin Haematol. 1986; 15(4):1037-80.
18. Michels SD, Mc Kenna RW, Arthur D, Burning RD. Therapy related acute myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985; 65:1364-72.
19. Miller KB. Clinical manifestation of acute myeloid leukaemia. In: Hoffman R, et al, editors. Hematology, Basic Principles and Practice. New York: Churchill Linivngstone; 1995. p.993-1013.
20. Novak A, Kruskic M, Ludoski M, Jurukovski V. Rapid method for obtaining high-quality chromosome banding in the study of hemopoietic neoplasia. Cancer Genet Cytogenet. 1994; 74:109-14.
21. Pedersen-Bjergaard J, Andersen MK, Cristiansen DH. Therapyrelated acute myeloid leukaemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000; 95:3273-9.
22. Pedersen-Bjergaard J, Philip P, Pedersen NT, Hou-Jensen K, Svejgaard A, Jensen G, et al. Acute nonlymphocytic leukaemia, preleukaemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patients. Cancer. 1984; 54:452-62.
23. Sandoval C, Pui CH, Bowman LC, Heaton D, Hurwitz CA, Raimondi SC, et al. Secondary acute myeloid leukaemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors and irradiation. J Clin Oncol. 1993; 11(6):1039-45.
24. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukaemia; the University of Chicago series. Blood. 2003; 102:43-52.
25. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med. 1993; 329:1152-6.
26. Sozzi G, Miozzo M, Orazi A, Calderone C, Castellano M, Viviani S, et al. Cytogenetic study in therapy-related myelodysplastic syndromes (t-ANLL). Br J Cancer. 1990; 61:425-8.
27. Stass S, Mirro J, Melvin S, Pui CH, Murphy SB, Williams D. Lineage switch in acute leukaemia. Blood. 1984; 64:701-6.
28. Winfield DA, Lilleyman JS. Secondary leukaemias. In: Whittaker JA, editor. Leukaemia. Oxford, London: Blackwell Scientific Publications; 1992. p.541-64.
29. Chambers KS, Chopyk LR, Chambers TJ, Schwartz EP, Dyffy PT. Development of leukaemia after doxorubicin and cisplatin treatment for ovarian cancer. Cancer. 1989; 64: 2459-61.
30. Blatt J, Olshan A, Gula MJ, Dickman PS, Zaranek B. Second malignancies in very-long-term survivors of childhood cancer. Am J Med. 1992; 93:57-60.
31. Boffetta P, Kaldor JM. Secondary malignancies following cancer chemotherapy. Acta Oncol. 1994; 33(6):591-8.
32. Blayney WD, Longo LD, Young CR, Greene HM, Hubbard MS, Postal GM, et al. Decreasing risk of leukaemia with prolonged follow up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med. 1987; 316(12):710-4.
33. Devereux S, Selassie TG, Vaughen Hudson G, Vaughen Hudson B, Linch DC. Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. BMJ. 1990; 301:1077-80.